Application of wolfberry glycopeptide in preparation of product for preventing and treating anxiety and depression
Through the preparation of wolfberry glycopeptide, the problem of major side effects of existing drugs in the treatment of postoperative depression and anxiety is solved, and a safer and more effective treatment effect is achieved.
Patent Information
- Application Number
- CN202510063368.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-01-15
- Publication Date
- 2025-03-28
AI Technical Summary
Existing drugs used to treat postoperative depression and anxiety have side effects and cannot achieve safe and affirmative efficacy in most patients, limiting their application in clinical practice.
Using wolfberry glycopeptide as the main component, the 3D molecular structure and biological activity extracted from combined with deionized water was developed to prevent and treat anxiety and depression.
Lycium barbarum glycopeptide significantly alleviates the anxiety and depression symptoms caused by surgery, and its effect is better than existing conventional drugs. It is also natural in origin, high in safety and has lower side effects.
Smart Images
Figure CN119700929A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine technology, and in particular to the application of Lycium barbarum glycopeptide in the preparation of products for preventing and treating anxiety and depression. Background Art
[0002] Mood disorders are a class of diseases that affect an individual's emotional state and emotional regulation, including mental illnesses such as depression, anxiety, or bipolar disorder. Patients usually show main characteristics such as low mood, self-isolation, negative cognition, and mania, and are also accompanied by weight gain and loss, appetite, sleep disorders, severe fatigue, and decreased attention. Mood disorders are also the third largest disease in the world in terms of total disease burden. Their etiology is unclear and is mainly related to biological factors, psychological factors, and social factors, and their pathogenesis is complex. Drugs used clinically to treat mood disorders include serotonin reuptake inhibitors, tricyclic antidepressants, tetracyclic antidepressants, monoamine oxidase inhibitors, norepinephrine reuptake inhibitors, etc. However, these drugs have certain side effects, such as bone metabolism disorders, sweating, drowsiness, diarrhea, dizziness, anxiety, constipation, dry mouth, nausea and vomiting, anorexia, tremor, etc., and are not suitable for long-term use, which limits their scope of use.
[0003] Surgery is the leading surgical treatment method, with more than 300 million surgeries performed worldwide each year. Postoperative depression (POD) may occur in patients due to significant changes in noxious stress response, body image or functional ability after surgery. It is estimated that approximately 10-30% of patients experience depression or anxiety in the perioperative period. With the increase in the number of surgeries and the influence of social and psychological factors, the proportion of patients with postoperative mood disorders has increased year by year. Many studies have also emphasized that mental and psychological problems such as depression and anxiety are risk factors for poor prognosis in postoperative patients. Clinical evidence further points out that mood disorders interact with surgical prognosis, which not only increases the difficulty of recovery, but also causes the course of the disease to be prolonged and difficult to cure, increases the risk of cardiovascular and cerebrovascular accidents, and even reduces life expectancy. At present, postoperative depression is often underestimated in clinical diagnosis, and intervention methods are limited. It is impossible to achieve safe and affirmative efficacy in most POD patients, which seriously restricts the feasibility of clinical treatment. Therefore, it is an urgent clinical problem to find a treatment method with safe and affirmative efficacy and high patient satisfaction to intervene in postoperative depression or anxiety that needs treatment. Summary of the invention
[0004] In view of this, the present invention provides a use of Lycium barbarum glycopeptide in the preparation of a product for preventing and treating anxiety and depression. The Lycium barbarum glycopeptide of the present invention has a good improvement and treatment effect on anxiety and depression, especially anxiety and depression caused by surgery.
[0005] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0006] The present invention provides the use of wolfberry glycopeptide in preparing products for preventing and treating anxiety and depression.
[0007] Preferably, the anxiety is anxiety caused by surgery, and the depression is depression caused by surgery.
[0008] Preferably, the mass content of the Lycium barbarum glycopeptide in the product is 0.001% to 100%.
[0009] Preferably, the dosage of the product is 10 mg / kg / d.
[0010] Preferably, the product is food or medicine.
[0011] Preferably, the pharmaceutical dosage forms include granules, tablets, capsules, pills, pellets, oral liquids, effervescent tablets, extracts, syrups, injections, sustained-release agents, controlled-release agents or targeted preparations; the food includes liquid beverages, powdered foods, paste foods or block foods.
[0012] Compared with the prior art, the beneficial technical effects of the present invention are:
[0013] Lycium barbarum polysaccharide is one of the most active components in wolfberry, and wolfberry glycopeptide is the active component further separated and extracted from wolfberry, and its activity can reach 1-2 orders of magnitude of wolfberry polysaccharide. Lycium barbarum glycopeptide extraction adopts 3D molecular structure and its biological activity extracted by combining wolfberry with deionized water. During the extraction process, small molecule impurities, especially small glycoprotein oligosaccharides therein, are removed. The application of wolfberry glycopeptide provided by the present invention in the preparation of products for the prevention and treatment of anxiety and depression breaks through its limitations in traditional applications, can significantly relieve anxiety and depression symptoms caused by surgery, and its effect is better than that of existing conventional drugs, and wolfberry glycopeptide is naturally derived, highly safe, and can be applied to people of different ages and health conditions, with the advantages of medicine and food homology, and low side effects. The wolfberry glycopeptide of the present invention can be developed in a variety of preparation forms (such as granules, injections, beverages, etc.), so as to realize the flexible use of wolfberry glycopeptide in different scenarios, and has a wide range of applications. The wolfberry glycopeptide of the present invention has abundant raw materials, mature technology, low production cost, can effectively reduce the overall development and use cost of anxiety and depression related products, and has high economic value. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] The present invention will be further described below in conjunction with the accompanying drawings.
[0015] Figure 1 Behavioral trajectories of different groups of mice in EPM;
[0016] Figure 2is the time that mice in different groups stayed in the open arms of EPM;
[0017] Figure 3 The open field test trajectory diagrams of different groups of mice;
[0018] Figure 4 is the distance moved by different groups of mice in the open field test;
[0019] Figure 5 It is the time that different groups of mice stay in the central area in the open field test;
[0020] Figure 6 is the immobility time of mice in different groups in the tail suspension test;
[0021] Figure 7 is the immobility time of different groups of mice in the forced swimming test;
[0022] Figure 8 This is the sugar water intake ratio of different groups of mice in the sugar water preference experiment. DETAILED DESCRIPTION
[0023] To further illustrate the present invention, the following examples are used to provide a detailed description. The Lycium barbarum glycopeptide of the present invention was purchased from Tianren Lycium barbarum Biotechnology, and the other raw materials were commercially available.
[0024] Example 1 Investigating the effect of Lycium barbarum glycopeptide on the behavior of surgery-induced anxiety model mice
[0025] (1) Modeling method:
[0026] Seven-week-old C57BL / 6 male mice were used and subjected to adaptive feeding for 1 week in a standard environment. The feeding conditions were as follows: humidity 40%-60%, temperature 22±2°C, 12-hour lighting day and night cycle (lighting at 8 o'clock), and sufficient food and water supply.
[0027] ① Normal group (Control): raised in a normal environment.
[0028] ②Surgery group (Saline): After 7 days of adaptive feeding, mice were surgically modeled as follows:
[0029] The mice were anesthetized with isoflurane, the surgical area was prepared, disinfected with iodine, and then a 0.5-1 cm incision was made through the skin and muscle layer lateral to the midline of the abdomen. During the operation, the small intestine was pulled intermittently for 10 minutes, and then the abdomen was gently explored for 5 minutes with a sterile cotton swab moistened with sterile saline. At the end of the operation, the covering muscle layer and skin layer were sutured, and lidocaine was infiltrated into the wound for local analgesia. The body temperature was maintained at 37°C during the recovery period of surgery and anesthesia. Mice were gavaged with saline for 7 days after surgery.
[0030] ③ Lycium barbarum glycopeptide group (LbGp): After adaptive feeding, surgical modeling was performed. The modeling steps were the same as those of the surgery group. After the operation, the mice were gavaged with Lycium barbarum glycopeptide for 7 days.
[0031] (2) Elevated plus maze test
[0032] The Elevated Plus Maze (EPM) is a commonly used experimental tool, mainly used to assess the anxiety state of rodents such as mice and rats. The design of this maze is based on the natural fear of animals to open spaces and heights, as well as their tendency to explore new environments. By observing the behavior of animals in the maze, researchers can infer their anxiety level.
[0033] Before the experiment of the present invention, the mice were placed in the experimental environment to adapt for 0.5 hours. During the experiment, the mice were gently placed in the central area facing the open arm, and then began a 5-minute elevated cross maze exploration activity. The number of times the mice entered the open arm and the closed arm and their stay time were recorded. The entire experiment must be carried out in a quiet and unmanned environment. After each mouse test, the open arm and the closed arm were wiped with 75% alcohol to eliminate the influence of the odor of the previous mouse on the next mouse experiment. The results are as follows: Figure 1-2 shown.
[0034] Depend on Figure 1 It can be seen that the behavioral trajectories of the normal group mice under normal conditions without any surgery or treatment showed a more complex path distribution, indicating that they had more exploratory behaviors in both the open and closed arms of the maze. This reflects the lower anxiety level under normal conditions. The behavioral trajectories of mice after surgical modeling were significantly reduced, mainly concentrated in the closed arms, showing a significant decrease in exploratory behavior in the open arms. This shows that surgery caused a significant increase in the anxiety level of mice. That is, mice in the surgical group showed anxiety-like behavior. The exploration time of the open arms (white dotted area) of the mice in the Lycium barbarum glycopeptide group in the elevated plus maze increased, showing a trend of improvement in anxiety levels, indicating that Lycium barbarum glycopeptide has a significant improvement effect on surgery-induced anxious mice, and has a good effect in treating and improving anxiety.
[0035] Depend on Figure 2 It can be seen that the mice in the normal group stayed in the open arms of EPM for the longest time, which is the natural exploratory behavior of mice in a healthy state, showing a good psychological state. The mice in the surgery group stayed in the open arms of EPM for the shortest time, indicating that their anxiety levels were significantly increased and they showed anxiety-like behaviors. The mice in the Lycium barbarum glycopeptide group stayed in the open arms of EPM for a shorter time than the normal group but significantly longer than the surgery group, indicating that Lycium barbarum glycopeptide has a significant improvement effect on surgery-induced anxious mice and has a good effect in treating and improving anxiety.
[0036] (3) Open field test
[0037] The Open Field Test is a widely used experimental method to evaluate the behavior of animals, especially rodents such as mice and rats. This test is mainly used to study aspects such as anxiety, exploratory behavior, and general activity levels. By observing how animals move and explore in an open but unfamiliar environment, researchers can gather information about their emotional state, motor skills, and adaptability to new environments.
[0038] During the experiment of the present invention, the experimental environment must be kept quiet. The mice are first placed in the experimental environment to adapt for 0.5 hours, and then the mice are gently placed in a box with a white inner wall and bottom and an inner diameter of 40cm×40cm. The number of times the mice enter the central area within 10 minutes and the activity time in the central area are recorded with a camera. After each mouse is tested, the residue must be cleaned and 75% alcohol is used to spray and wipe to remove the odor to prevent the impact on the subsequent experimental mice. The time the mice enter the central area is used as a detection indicator to judge the autonomous activity and anxiety and depression level of the mice. The results are as follows Figure 3-5 shown.
[0039] Depend on Figure 3 It can be seen that the tracks of mice in the normal group are widely and evenly distributed, showing that they have carried out a lot of exploratory behaviors in both the central and peripheral areas, indicating that the mice in the normal group have low anxiety levels and strong mobility. The tracks of mice in the surgical group were significantly reduced and concentrated in the peripheral areas close to the wall, and the number of times they entered the central area was significantly reduced. This shows that the activity of mice after surgical modeling decreased, there was obvious avoidance behavior in the central open area, and the anxiety level increased significantly. That is, mice in the surgical group showed anxiety-like behavior. The exploration time of mice in the Lycium barbarum glycopeptide group in the central area of the open field (white box area) increased, and the track distribution was closer to that of the normal group. It shows that Lycium barbarum glycopeptide significantly improved the anxiety behavior of mice induced by surgery and improved their ability to explore the central area, indicating that Lycium barbarum glycopeptide has a significant improvement effect on surgically induced anxious mice, and has a good effect in treating and improving anxiety.
[0040] Depend on Figure 4 It can be seen that there is no significant difference in the moving distance of mice in the normal group, the surgery group, and the Lycium barbarum glycopeptide group, indicating that there is no change in the activity of the three groups of mice.
[0041] Depend on Figure 5It can be seen that the mice in the normal group stayed in the central area the longest, indicating that the mice in the normal group had the lowest anxiety level without any intervention and were able to freely explore the open central area, reflecting their high adaptability and low avoidance behavior. The mice in the surgery group stayed in the central area the shortest time, that is, the mice tended to avoid the central open area and choose the "safe area" closer to the periphery, which is a typical high-anxiety behavioral response. The time that the mice in the Lycium barbarum glycopeptide group stayed in the central area was shorter than that of the normal group but significantly higher than that of the surgery group, indicating that Lycium barbarum glycopeptide has a significant improvement effect on surgery-induced anxious mice and has a good effect in treating and improving anxiety.
[0042] (4) Tail suspension test
[0043] The Tail Suspension Test (TST) is a commonly used experimental method to assess depression-like behavior in rodents. This test measures the effectiveness of antidepressant drugs based on the amount of time an animal remains immobile while suspended.
[0044] Before the experiment, the mice were placed in the experimental environment to adapt for 0.5 hours. The tails of the mice were suspended from the hanging rod of the device using medical tape. The tape should be wrapped close to the tip of the tail of the animal, about 1 cm away from the tip of the tail, to avoid affecting the activity of the animal. The experimental time was 6 minutes, and the resting time of the mice in the last 4 minutes was recorded and analyzed. After the experiment, the tape was gently pulled off the tail, and the mice in each group were returned to their original environment for feeding. The results are as follows Figure 6 shown.
[0045] Depend on Figure 6 It can be seen that the mice in the normal group had the shortest immobility time, indicating that the mice in the normal group showed strong struggle and activity ability, and no depressive-like behavior. The mice in the surgery group had the longest immobility time, that is, the mice showed a higher sense of helplessness and behavioral inhibition, which is consistent with the characteristics of depression model animals. The mice in the Lycium barbarum glycopeptide group stayed in the central area longer than the normal group but significantly shorter than the surgery group, indicating that Lycium barbarum glycopeptide has a significant improvement effect on surgery-induced depressed mice and has a good effect in treating and improving anxiety.
[0046] (5) Forced swimming test
[0047] The forced swimming test (FST) is an animal behavioral experimental method used to evaluate the effects of antidepressants. It is mainly used in the study of antidepressants. It simulates an inescapable stress environment and observes the behavioral responses of animals to evaluate the effects of antidepressants.
[0048] Before the experiment, the mice were placed in the experimental environment to adapt for 0.5 hours. A transparent bucket with a diameter of 10 cm and a height of 25 cm was used to add tap water, the temperature was controlled at about 25°C, the swimming time was 6 minutes, and the swimming time and immobility time in the last 4 minutes were recorded to evaluate the depression state. Figure 7 shown.
[0049] Depend on Figure 7 It can be seen that the mice in the normal group had the shortest immobility time, and showed strong activity and stress resistance in the stressful environment where they could not escape, and had no depressive-like behavior. The mice in the surgery group had the longest immobility time and showed depressive-like behavior. The mice in the Lycium barbarum glycopeptide group stayed in the central area longer than the normal group but significantly shorter than the surgery group, indicating that Lycium barbarum glycopeptide had a significant improvement effect on surgery-induced depressed mice and had a good effect in treating and improving anxiety.
[0050] (6) Sugar water preference experiment
[0051] The Sucrose Preference Test (SPT) is a behavioral test used to assess the emotional state of experimental animals. The test is based on the natural preference of rodents for sweets. Under normal circumstances, animals tend to choose sweet sucrose water rather than pure water. However, when animals are depressed, addicted, or have other mental and behavioral disorders, their preference for sucrose water will be significantly reduced, manifested as loss of pleasure or interest, and is particularly used to detect the happiness level and depression symptoms of animals.
[0052] Each group of mice was housed in a single cage and adapted on the first day. Drinking water was added to both bottles. On the second day, one bottle of drinking water was replaced with a 2% sucrose solution. On the third day, the drinking water and sucrose water were swapped. On the fourth day, data were collected and the sucrose preference of each group of mice was calculated. Figure 8 shown.
[0053] Depend on Figure 8 It can be seen that the normal group mice had the highest sugar water intake ratio, indicating that the normal group mice showed a high preference for sugar water, healthy emotional state, no anhedonia or loss of interest, and no depressive-like behavior. The surgical group mice had the lowest sugar water intake ratio, and the intake ratio was significantly reduced, indicating that they had anhedonia and loss of interest, showing typical depressive-like behavior. Although the sugar water intake ratio of the Lycium barbarum glycopeptide group mice was lower than that of the normal group, it was significantly higher than that of the surgical group, indicating that Lycium barbarum glycopeptide had a significant improvement effect on surgically induced depressed mice and had a good effect in treating and improving anxiety.
[0054] The above-mentioned embodiments only express several implementation methods of the present invention, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.
Claims
1. Application of Lycium barbarum glycopeptide in the preparation of products for preventing and treating anxiety and depression.
2. The use according to claim 1, characterized in that: The anxiety is anxiety caused by surgery, and the depression is depression caused by surgery.
3. The use according to claim 1, characterized in that: The mass content of the wolfberry glycopeptide in the product is 0.001% to 100%.
4. The use according to claim 1, characterized in that: The dosage of the product is 10 mg / kg / d.
5. The use according to claim 1, characterized in that: The product is a food or a medicine.
6. The use according to claim 5, characterized in that: The drug includes a pharmaceutically acceptable carrier.
7. The use according to claim 5, characterized in that: The dosage forms of the medicine include granules, tablets, capsules, pills, dripping pills, oral liquids, effervescent tablets, extracts, syrups, injections, sustained-release agents, controlled-release agents or targeted preparations.
8. The use according to claim 5, characterized in that: The food includes liquid beverages, powdered food, paste food or block food.
9. A product for preventing and treating anxiety and depression, characterized in that: Including wolfberry glycopeptide.
10. The product for preventing and treating anxiety and depression according to claim 9, characterized in that: The dosage of the product is 10 mg / kg / d.